
Drs Lisa VanWagner and Kathleen Corey examine how MASLD should shape cardiovascular risk assessment, statin use, and treatment decisions.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep6-2026a1000aay. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5
Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiovascular Disease https://pubmed.ncbi.nlm.nih.gov/41124780/
FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis
Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease https://pubmed.ncbi.nlm.nih.gov/32707340/
Non-Alcoholic Fatty Liver Disease and Risk of Fatal and Non-Fatal Cardiovascular Events: An Updated Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34555346/
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/37807924/
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/41824552/
CVD Risk Estimator Plus https://tools.acc.org/cvd-risk-estimator-plus/#!/calculate/estimate/
Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease: A Review https://pubmed.ncbi.nlm.nih.gov/34613362/
Risk-Associated and Clinically Informative Biomarkers for Cardiovascular Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41624044/
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein https://pubmed.ncbi.nlm.nih.gov/18997196/
Statin Liver Safety in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Metanalysis https://pubmed.ncbi.nlm.nih.gov/34133035/
Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance https://pubmed.ncbi.nlm.nih.gov/39422487/
Effect of Non-Statin Lipid-Lowering Therapy on Hepatic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/41048606/
The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective https://pubmed.ncbi.nlm.nih.gov/24084292/
The Role of FibroScan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/
Transcatheter Left Atrial Appendage Closure: Devices Available, Pitfalls, Advantages, and Future Directions https://pubmed.ncbi.nlm.nih.gov/39493945/
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More episodes from "Medscape InDiscussion: MASLD"



Don't miss an episode of “Medscape InDiscussion: MASLD” and subscribe to it in the GetPodcast app.




